Prostate Cancer

PSA failure in men with localized, intermediate- or high-risk prostate cancer was associated with increased all-cause mortality in only those patients with no or minimal comorbidity.

A model based on a series of PSA tests can predict the time to relapse in prostate cancer patients who underwent radical prostatectomy, according to a new study.

The incidence of early-stage prostate cancer in men 50 years and older continued a decline reported earlier, with lower rates in 2013 compared to 2012. This is a likely result of the October 2011 recommendation from the USPSTF against routine PSA testing in all men.

Noncoding RNA appears to be involved in the epigenetic regulation of prostate cancer, according to findings published in Nature Genetics.

In this interview we discuss PSA screening for prostate cancer, the compromised results of the PLCO trial, and more.

Mapping the interactions of metastatic prostate tumor gene expression and protein phosphorylation can yield detailed, patient-specific signalling pathway diagrams, and help to identify “master-switch” tumor progression-driving targets for personalized treatment.

Androgen-deprivation therapy (ADT) is associated with shortened survival in African American men with favorable-risk prostate cancer, according to a new study. The results suggest ADT should be reserved for men with higher risk disease.

Determining the presence of AR-V7 in prostate cancer patients could potentially save the US healthcare system $150 million each year by preventing unnecessary treatment.

Outcomes after salvage radiotherapy are affected by variables related to prostatectomy for men with prostate cancer, but its use at lower PSA levels may improve outcomes.

Robot-assisted and open radical surgeries for prostate cancer have similar outcomes for patients at 3 months, according to clinical trial results.

Metastatic prostate cancer is more strongly associated than localized disease with germline mutations in DNA repair genes like BRCA1 and BRCA2.

Canadian researchers have tentatively identified urine protein signatures that appear to differentiate aggressive from low-risk prostate tumors.

A randomized phase III trial found that a hypofractionated radiotherapy regimen was not superior to, but generally equivalent to a conventional radiotherapy scheme in men with localized prostate cancer.

A database analysis showed that the addition of external beam radiotherapy to ADT significantly improves overall survival in men with metastatic prostate cancer.

Higher than average PSA levels in middle age may be predictive of a higher risk of lethal prostate cancer later in life.

In this peer-to-peer discussion, Dr. Loeb and Dr. Choyke discuss new developments in active surveillance for prostate cancer.

Experimental, minimally invasive “liquid biopsy” blood tests might soon help to personalize prostate cancer treatment by predicting androgen resistance and survival benefits from particular treatments.

Use of multiparametric MRI could allow a significant portion of men with elevated PSA levels to avoid undergoing a biopsy without missing clinically significant prostate cancers.

The use of ADT along with modern dose-escalated RT does not improve survival vs RT alone in men with favorable intermediate-risk prostate cancer.

A new study published in Nature Communications is suggesting that castration-resistant prostate cancer has particular metabolic characteristics that may open new possibilities for treatment.

We will review how PARP inhibitors function as a class, review the molecular features that sensitize cancer cells to this therapy, and discuss the data supporting its potential for patients with prostate cancer.

Having said that, PARP inhibition is one of the most promising approaches for “precision therapy” so far. Within the next few years and with the help of ongoing clinical trials, we should have a better understanding of whether or not the high expectations raised will be translated into clinical reality.

Only one in three men with prostate cancer received care in accordance with guidelines for active surveillance, according to a new study conducted in Michigan.

Declines in the rates of cigarette smoking in several states mirrored declines in prostate cancer deaths between 1999 and 2010, according to a new epidemiologic analysis.

Prostate cancer patients who kept up a moderate to high level of physical activity had better survival prognoses compared with their more sedentary counterparts.